This application is for a five-year extension of funding for the Diabetic Retinopathy Clinical Research Network (DRCR.net) Coordinating Center. The objective of the DRCR.net is to develop and maintain a collaborative network to facilitate multicenter clinical research on diabetic retinopathy, diabetic macular edema and associated conditions, leading and growing causes of vision impairment and blindness in the United States and throughout the world. Its priorities include involvement of community-based practices as well as university-based centers and to collaborate with industry to facilitate investigations and opportunities otherwise not possible, but to do so in a manner consistent with the Network's dedication to academic integrity and optimal clinical trial performance. The Coordinating Center plays a key role in the Network's ability to achieve its goals. During the next funding cycle, the network proposes to complete 5 protocols that are expected to be in progress at the time the funding period begins, initiate approximately 10 new protocols (approximately 1 new major protocol and 1 new minor protocol per year) in diabetic retinopathy, diabetic macular edema and associated conditions, develop and implement new methods for electronic data capture of retinal images to facilitate the conduct of diabetic retinopathy clinical trials, continue to expand the DRCR.net by soliciting the participation of new sites and encouraging the involvement of investigators who recently have completed fellowship training (see Operations Center proposal), continue to educate the DRCR.net investigators on the principles of clinical research, and mentor selected retina specialists to be leaders in clinical trials with specific reference to diabetic retinopathy and associated diseases.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10EY014231-11
Application #
8212545
Study Section
Special Emphasis Panel (ZEY1-VSN (03))
Program Officer
Schron, Eleanor
Project Start
2002-09-30
Project End
2013-12-31
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
11
Fiscal Year
2012
Total Cost
$6,500,000
Indirect Cost
$861,188
Name
Jaeb Center for Health Research, Inc.
Department
Type
DUNS #
957043193
City
Tampa
State
FL
Country
United States
Zip Code
33647
Gross, Jeffrey G; Glassman, Adam R (2016) A Novel Treatment for Proliferative Diabetic Retinopathy: Anti-Vascular Endothelial Growth Factor Therapy. JAMA Ophthalmol 134:13-4
Beaulieu, Wesley T; Bressler, Neil M; Melia, Michele et al. (2016) Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial. Am J Ophthalmol 170:206-213
Bressler, Susan B; Glassman, Adam R; Almukhtar, Talat et al. (2016) Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema. Am J Ophthalmol 164:57-68
Bressler, Susan B; Ayala, Allison R; Bressler, Neil M et al. (2016) Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. JAMA Ophthalmol 134:278-85
Wells, John A; Glassman, Adam R; Jampol, Lee M et al. (2016) Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. JAMA Ophthalmol 134:127-34
Wells, John A; Glassman, Adam R; Ayala, Allison R et al. (2016) Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology 123:1351-9
Bressler, Susan B; Melia, Michele; Glassman, Adam R et al. (2015) RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina 35:2516-28
Diabetic Retinopathy Clinical Research Network; Wells, John A; Glassman, Adam R et al. (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193-203
Aiello, Lloyd Paul; Ayala, Allison R; Antoszyk, Andrew N et al. (2015) Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control: A Randomized Clinical Trial. JAMA Ophthalmol 133:888-96
Bressler, Susan B; Almukhtar, Talat; Bhorade, Anjali et al. (2015) Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol 133:589-97

Showing the most recent 10 out of 65 publications